Logo

Medicines Development for Global Health's (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

Share this

Medicines Development for Global Health's (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

Shots:

  • The approval is based on two clinical studies results assessing Moxidectin vs SoC Ivermectin in patients with river blindness aged ≥ 12 yrs.
  • The study resulted in meeting 1EPswith superiority of Moxidectin vs SoC Ivermectin and resulted in suppression of microfilariae in the skin
  • Moxidectin (8mg- PO) is macrocyclic lactone anthelmintic medication active against O.volvulus microfilariae and has also received FDA’s PRV on 13 Jun- 2018 with its accelerated NDA review from 10 to 6mos.

Ref: Medicines Development for Global Health | Image: CmocroI

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions